Skip to Content

Asparaginase erwinia chrysanthemi Pregnancy and Breastfeeding Warnings

Asparaginase erwinia chrysanthemi is also known as: Erwinaze

Medically reviewed on August 6, 2018

Asparaginase erwinia chrysanthemi Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk.

US FDA pregnancy category: C

In animal studies, maternal toxicities of decreased body weight and decreased body weight gain and fetal findings of increased incidence of partially undescended thymic tissue, increased post-implantation loss, decreased number of live fetuses, and gross abnormalities were observed. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Asparaginase erwinia chrysanthemi Breastfeeding Warnings

Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide